Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 15  |  Issue : 7  |  Page : 1629--1634

Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer


Zhigang Wei, Xia Yang, Xin Ye, Guanghui Huang, Wenhong Li, Xiaoying Han, Jiao Wang, Min Meng, Yang Ni, Zhigeng Zou, Qiang Wen 
 Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Correspondence Address:
Dr. Xin Ye
Department of Oncology, Shandong Provincial Hospital Affiliated, To Shandong First Medical University, 324 Jingwuweiqi Road, Jinan, Shandong 250021
China

Aim: The present study evaluated the safety and efficacy of camrelizumab (a programmed death-1 antibody) in combination with microwave ablation (MWA) in advanced non-small cell lung cancer (NSCLC). Materials and Methods: A total of 21 patients were prospectively enrolled. MWA was performed in 25 pulmonary lesions during 21 sessions. Camrelizumab was administered 5–7 days after MWA as a dose of 200 mg, which was repeated every 2 weeks until disease progression or intolerable toxicities. The primary endpoints were safety and the objective response rate (ORR). Other endpoints included progression-free survival (PFS) and overall survival (OS). Results: The technical success rate was 100%. No treatment-associated deaths were identified. Major complications, minor complications, and side effects of MWA were observed in 9, 8, and 14 patients, respectively. The main major complications included pneumothorax, pneumonia, hemorrhage, and pleural effusion. The adverse events of camrelizumab included reactive skin capillary hyperplasia (n = 9), hypothyroidism (n = 5), pneumonia (n = 4), fatigue (n = 2), leukopenia (n = 1), and neutropenia (n = 1). Grade 2 and 3 camrelizumab adverse events were identified in eight and three patients, respectively. The ORR was 33.3%, with two patients achieving complete response and five patients achieving partial response. The median PFS was 5.1 months and OS was not reached. Conclusions: Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports.


How to cite this article:
Wei Z, Yang X, Ye X, Huang G, Li W, Han X, Wang J, Meng M, Ni Y, Zou Z, Wen Q. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.J Can Res Ther 2019;15:1629-1634


How to cite this URL:
Wei Z, Yang X, Ye X, Huang G, Li W, Han X, Wang J, Meng M, Ni Y, Zou Z, Wen Q. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. J Can Res Ther [serial online] 2019 [cited 2020 Sep 26 ];15:1629-1634
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2019;volume=15;issue=7;spage=1629;epage=1634;aulast=Wei;type=0